Plain-English translation of NCT05655650 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking for biological markers—measurable warning signs found in blood, brain scans, and eye imaging—that could help doctors identify Alzheimer's disease earlier, before serious cognitive decline occurs. Researchers will follow four groups of people (those with normal thinking, those with memory concerns only, those with mild cognitive problems, and those with dementia) over six years to understand how these markers change over time. The goal is to find patterns that could one day allow earlier diagnosis and treatment.
Alzheimer's disease damages the brain long before people notice memory problems. By identifying biological markers—like changes visible in brain imaging or detectable in blood—doctors hope to catch the disease in its earliest stages, when treatments might be more effective. This research could eventually lead to earlier diagnosis and better outcomes for people at risk.
You likely qualify if…
You likely don't qualify if…
At your first visit, you'll have cognitive tests (memory and thinking assessments), blood drawn, a brain MRI scan, a brain PET scan, and eye imaging. Then you'll return once per year for six years; at most visits you'll have cognitive tests again, and at your final year-six visit you'll also have repeat eye imaging. In total, this is a six-year commitment with one baseline visit and six follow-up visits.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Hong Kong